

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of Sinopharm Tech Holdings Limited.



SINOPHARM TECH HOLDINGS LIMITED

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Sinopharm Tech Holdings Limited (the “**Company**”) dated 27 July 2022 (the “**Announcement**”) in relation to the connected transaction of the Loan Capitalisation involving issue of new Shares under specific mandate. Terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, amongst other information, (i) further information on the Loan Capitalisation; (ii) the respective advice from the Independent Board Committee and the independent financial adviser on the terms of the Loan Capitalisation Agreement and the transactions contemplated thereunder; and (iii) a notice of EGM and a form of proxy, will be despatched to the Shareholders on or before 31 August 2022.

As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the despatch date of the Circular will be delayed to a date falling on or before 30 September 2022.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 31 August 2022

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.